about
The relationship between hemoglobin levels and endothelial functions in diabetes mellitusCombined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilationSoluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.Differential adipogenic and inflammatory properties of small adipocytes in Zucker Obese and Lean rats.ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.P-wave dispersion and its relationship to aortic elasticity in young prehypertensive patients.Endothelial dysfunction and fetuin A levels before and after kidney transplantation.The plasma levels of soluble P-selectin in subjects with prediabetes.Prostate cancer and adiponectin.The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan.Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus.Comment on: Jones et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care 2011;34:828-837.FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: the impact of metabolic syndrome.Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease.Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism.Adipokines and cytokines in non-alcoholic fatty liver disease.Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease.Plasma adiponectin and insulin resistance in new onset hypertension.Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease.Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?Adipocytokine levels in chronic pancreatitis.Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease.Rosiglitazone for nonalcoholic steatohepatitis.Re: Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients.Asymmetric dimethylarginine levels decrease because of insulin infusion: is it an unexpected finding?LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia.Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function.Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model.The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation.The effect of the renin-angiotensin system blockage on the plasma adiponectin levels and insulin sensitivity in patients with chronic kidney disease.Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease.Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions.Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
P50
Q33571310-D72DB447-F370-4058-8DF0-363D7D8245D9Q33944773-38698164-5FE7-4186-9C35-F02AE812F670Q34751855-467F9CCE-45EB-4800-9F1E-29246A2C3B6FQ35758553-D0E263F2-778A-45E4-8A51-DE8D413E82AEQ36292566-920D0CBD-B198-4022-A62E-19F52A5D2D41Q36677348-05F439E6-B6B3-401F-A085-9C6D4E6A8A02Q36689781-7E460941-F9EB-42B3-9BFA-A9A1F35FFEABQ37415728-B35DCA36-7C9D-4393-9E42-3C8DF638C48EQ39736220-1A76E029-900B-4800-9F95-6F85C13EE675Q39944374-F20CB046-E085-45D3-B5C6-ACCA3D6CB1AFQ40240014-E339B29C-46E4-4ED0-AD0F-0A80BB6FA1D7Q40293267-6984359E-CD53-4DBC-BC81-97F95DD8DF56Q40418631-DEF5A936-812E-4DEC-9695-1C195D1D5936Q41946641-3E992E46-43CD-4D7F-8A5D-FFD80EB6050FQ42853671-3A94B18D-75B1-4308-A53B-C976FC9AB7A1Q42945001-2BDD78A5-0E6F-43E7-9FD5-09C4C0360D63Q42976674-ACEEF16A-06B0-4AF9-90BE-0775B26ED958Q43116384-F8F60120-8916-4964-B629-C69141940744Q43711916-EF14337E-5D28-484C-80E4-220655B3A2C4Q43764186-55C6FF96-ACDD-4ECB-930E-1EB4A9458D4EQ44182633-30AF1100-5B97-409F-99BF-8BC405D2C688Q44508218-CB59B7C1-C8D6-41D4-AAC3-5401EF664BC7Q44774081-16ECC712-A07C-47A6-B2B5-8CB61CC3EE52Q44839458-BF37BE2C-E461-47F7-B601-50DBF51EFBFBQ45343724-199473A1-852D-46B6-9326-0203E3B98026Q46032485-3B19B60D-576A-402A-81D6-FE253190C184Q46038567-D64F9D74-2FDC-4806-B2C2-E499A4A066C5Q46099868-4C2A33FF-006B-4DCB-BB67-67A23A4F6BB7Q46243304-F429570E-9721-4BF5-AA2F-40AF4B7447EDQ46300254-3F9E8D92-954A-4564-A727-6A0D8D6F6B4CQ46305532-1F078DBD-7CC4-49A2-824B-E9B1CE6ABBC5Q46323342-7A4AB741-D0BA-44B7-87EF-DA13F2F8A584Q46354917-8E5DD5A2-86AF-4523-8602-2179CCD264B2Q46823385-D066F88F-BF84-4338-9FAD-1BF5F0495CE1Q46867931-E19813CA-BF58-4CBA-A733-569B58F60081Q46868398-340A1CE6-0E06-4C6E-ACE6-3ECB68C54AA2Q47735086-797CE499-9804-4707-827C-23CACE305154Q47804370-C2FB82F9-49B1-4EF2-8F93-55395EC536C5Q48388854-4231ADAA-439A-4502-996E-960DC91B2B9AQ50535094-740D6123-68F9-4B8B-94E5-9FD8FFE4E4C3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alper Sonmez
@ast
Alper Sonmez
@en
Alper Sonmez
@es
Alper Sonmez
@nl
Alper Sonmez
@sl
type
label
Alper Sonmez
@ast
Alper Sonmez
@en
Alper Sonmez
@es
Alper Sonmez
@nl
Alper Sonmez
@sl
prefLabel
Alper Sonmez
@ast
Alper Sonmez
@en
Alper Sonmez
@es
Alper Sonmez
@nl
Alper Sonmez
@sl
P106
P1153
7003480380
P21
P31
P496
0000-0002-9309-7715